{
    "clinical_study": {
        "@rank": "55596", 
        "arm_group": {
            "arm_group_label": "Treatment (monoclonal antibody)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive a tracer dose of iodine I 131 monoclonal antibody CC49-deltaCH2 IV on day 1 and a therapy dose over 30 minutes on day 8.\nCohorts of 3-5 patients receive escalating doses of iodine I 131 monoclonal antibody CC49-deltaCH2 until the MTD is determined. The MTD is defined as the dose at which 3 of 5 patients experience grade 3 or greater toxicity while 0-2 of 5 patients experience reversible grade 4 hematologic toxicity."
        }, 
        "brief_summary": {
            "textblock": "Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in\n      treating patients who have recurrent or persistent metastatic colorectal cancer.\n      Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing\n      substances to them without harming normal cells. Radiolabeled monoclonal antibody therapy\n      may be effective treatment for colorectal cancer"
        }, 
        "brief_title": "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer", 
        "condition": [
            "Adenocarcinoma of the Colon", 
            "Adenocarcinoma of the Rectum", 
            "Recurrent Colon Cancer", 
            "Recurrent Rectal Cancer", 
            "Stage IV Colon Cancer", 
            "Stage IV Rectal Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Colonic Neoplasms", 
                "Rectal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Determine the maximum tolerated dose of iodine I 131 monoclonal antibody CC49-deltaCH2\n      (deleted CH2 region) in patients with colorectal cancer.\n\n      II. Determine the toxic effects, plasma pharmacokinetics, whole body biodistribution, and\n      conjugate stability of this drug in these patients.\n\n      III. Determine the ability of this drug to localize to tumor sites in these patients.\n\n      IV. Determine the immune response in patients treated with this drug.\n\n      OUTLINE: This is a dose-escalation study.\n\n      Patients receive a tracer dose of iodine I 131 monoclonal antibody CC49-deltaCH2 IV on day 1\n      and a therapy dose over 30 minutes on day 8.\n\n      Cohorts of 3-5 patients receive escalating doses of iodine I 131 monoclonal antibody\n      CC49-deltaCH2 until the maximum tolerated dose (MTD) is determined. The MTD is defined as\n      the dose at which 3 of 5 patients experience grade 3 or greater toxicity while 0-2 of 5\n      patients experience reversible grade 4 hematologic toxicity.\n\n      Patients are followed weekly for a minimum of 7 weeks and then every 6 weeks until disease\n      progression."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed metastatic adenocarcinoma of the colon or rectum\n\n               -  Not amenable to surgical resection\n\n               -  Recurrent or persistent disease after standard surgery, radiotherapy, and\n                  chemotherapy, including fluorouracil and irinotecan\n\n          -  TAG-72 positive\n\n          -  Performance status - ECOG 0-2\n\n          -  WBC greater than 3,500/mm^3\n\n          -  Platelet count greater than 125,000/mm^3\n\n          -  Hemoglobin greater than 10 g/dL\n\n          -  No nucleated RBC or significant teardrop RBC morphology\n\n          -  Bilirubin less than 1.5 mg/dL\n\n          -  SGOT/SGPT less than 4 times normal\n\n          -  Hepatitis B surface antigen negative\n\n          -  Creatinine less than 2.0 mg/dL\n\n          -  HIV negative\n\n          -  No other malignancy within the past 5 years except basal cell skin cancer\n\n          -  No allergy to iodine\n\n          -  No detectable antibody to monoclonal antibody CC49\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n          -  At least 3 weeks since prior immunotherapy and recovered\n\n          -  No prior bone marrow or stem cell transplantation\n\n          -  No other concurrent immunotherapy\n\n          -  See Disease Characteristics\n\n          -  At least 3 weeks since prior chemotherapy and recovered\n\n          -  No concurrent chemotherapy\n\n          -  See Disease Characteristics\n\n          -  At least 3 weeks since prior radiotherapy and recovered\n\n          -  No prior radiotherapy to more than 25% of red marrow\n\n          -  No concurrent radiotherapy\n\n          -  See Disease Characteristics\n\n          -  At least 3 weeks since prior surgery and recovered"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 13, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00023933", 
            "org_study_id": "NCI-2012-02406", 
            "secondary_id": [
                "UAB 9846", 
                "CDR0000068877"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Treatment (monoclonal antibody)", 
            "description": "Given IV", 
            "intervention_name": "iodine I 131 monoclonal antibody CC49-deltaCH2", 
            "intervention_type": "Drug", 
            "other_name": [
                "131I-HuCC49-deltaCH2", 
                "131I-MOAB CC49-deltaCH2"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal", 
                "Iodine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Birmingham", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "35294"
                }, 
                "name": "University of Alabama at Birmingham"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Trial of 131I-HuCC49^CH2 for Colon Cancer", 
        "overall_official": {
            "affiliation": "University of Alabama at Birmingham", 
            "last_name": "Ruby Meredith", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Maximum tolerated dose of 131I-HuCC49^CH2 based on dose-limiting toxicities", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00023933"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Immune response", 
            "safety_issue": "No", 
            "time_frame": "Up to 54 weeks"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "October 2001", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }, 
    "geocoordinates": {
        "University of Alabama at Birmingham": "33.521 -86.802"
    }
}